Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323191 · ClinicalTrials.gov registry record · Phase 1
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
A Phase 1 study of Solid Cancers, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 221
- Enrollment target
- 12
- Study locations
NCT02323191 is a Phase 1 study of Solid Cancers that has completed, run by Hoffmann-La Roche. The registered enrollment target is 221 participants. The trial reports 12 study locations across 5 states.
The verdict
NCT02323191, a Phase 1 study of Solid Cancers, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 221 participants
- Enrollment target
- 12
- Study locations
Study Summary
This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participants who receive emactuzumab and atezolizumab will continue to receive study drug as long as they experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data, biopsy results (if available), and clinical status, or withdrawal of consent.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Emactuzumab
Study Locations (12)
Other
- Cliniques Universitaires St-Luc - Brussels
- Centre Leon Berard; Departement Oncologie Medicale - Lyon
- Institut Claudius Regaud; Departement Oncologie Medicale - Toulouse
- Institut Gustave Roussy; Departement Oncologie Medicale - Villejuif
- Hospital del Mar; Servicio de Oncologia - Barcelona
- Centro Integral Oncológico Clara Campal Ensayos Clínicos START - Madrid
Massachusetts
- Massachusetts General Hospital. - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber - Harvard - Boston
Connecticut
- Yale Cancer Center; Medical Oncology - New Haven
New York
- Memorial Sloan-Kettering Cancer Center Breast & Imaging Center - New York
Navarre
- Clinica Universitaria de Navarra; Servicio de Oncologia - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2020-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02323191
The ClinicalTrials.gov registry entry for NCT02323191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Cancers appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02323191 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, Massachusetts, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02323191 about?
NCT02323191 is a clinical study titled "A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors". This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participant...
What is the current status of trial NCT02323191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 221 participants. The study started on 2015-01-19. Estimated completion is 2020-08-21.
What conditions does trial NCT02323191 study?
This clinical trial studies the following conditions: Solid Cancers.
What interventions are being tested in trial NCT02323191?
The interventions under investigation include: Atezolizumab (DRUG), Emactuzumab (DRUG).
Who is sponsoring clinical trial NCT02323191?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02323191 being conducted?
This trial has 12 study locations across Connecticut, Massachusetts, New York, Navarre. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.